申请人:Boehringer Ingelheim International GmbH
公开号:US20210121473A1
公开(公告)日:2021-04-29
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R
1
, R
2
, R
3
, R
4
, R
5
, R
6
and R
7
are as defined herein, for use in the treatment of diseases or disorders that can be alleviated by sGC activation or potentiation, selected from chronic liver diseases, Non-Alcoholic Steatohepatitis (NASH), cirrhosis and portal hypertension.